Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.47 |
| ▸ | FYN | P06241 | 6/20 | 0.37 |
| ▸ | GRK5 | P34947 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14785872 | 0.99 | HRH4 (0.46) | HRH4FYNGRK5CYP17A1SMPD3 | |
| SCHEMBL14785798 | 0.94 | HRH4 (0.43) | HRH4FYNGRK5CYP17A1SMPD3 | |
| SCHEMBL2401946 | 0.92 | HRH4 (0.40) | HRH4FYNGRK5SMPD3HRH3 | |
| SCHEMBL2401829 | 0.92 | HRH4 (0.40) | HRH4FYNGRK5SMPD3HRH3 | |
| SCHEMBL2401823 | 0.92 | HRH4 (0.40) | HRH4FYNGRK5SMPD3HRH3 | |
| Citric Acid SCHEMBL14785771 | 0.87 | HRH4 (0.38) | HRH4FYNGRK5SMPD3LRRK2 | |
| SCHEMBL2401793 | 0.82 | ALDH1A1 (0.48) | HRH4FYNGRK5CYP17A1HRH3 | |
| SCHEMBL2406219 | 0.82 | HRH4 (0.51) | HRH4HRH3HTR3A | |
| SCHEMBL15353914 | 0.81 | ALDH1A1 (0.42) | FYNGRK5CYP17A1 | |
| SCHEMBL14785994 | 0.80 | HRH4 (0.40) | HRH4FYNSMPD3HRH3HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859550-B2 | Heterocyclic inhibitors of histamine receptors for the treatment of disease | KALYPSYS, INC. (US) | 2014-10-14 | — | — | US | claimed |
| US-20130245001-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2013-09-19 | — | — | US | claimed |
| WO-2013039785-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2013-03-21 | — | — | WO | claimed |
| EP-2545058-B1 | TETRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS INHIBITORS OF HISTAMINE RECEPTORS | KALYPSYS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-8859550-B2 | Heterocyclic inhibitors of histamine receptors for the treatment of disease | KALYPSYS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859550-B2 | Heterocyclic inhibitors of histamine receptors for the treatment of disease | KALYPSYS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859550-B2 | Heterocyclic inhibitors of histamine receptors for the treatment of disease | KALYPSYS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130245001-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245001-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245001-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013039785-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013039785-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| EP-2545058-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2011112766-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885FYN 2373/4885GRK5 292/4885 |
| US-20130245001-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH2, HRH3 | HRH4 1/4885FYN 2350/4885GRK5 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.